Disparities in OUD treatment: Buprenorphine vs. naltrexone
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Regulatory decision-making depends on evidence that reflects how medical products perform in real-world use, not only in controlled trials. For more than a decade, the Food and Drug Administration has relied on real-world data and real-world...
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
(Part 1) When clients see real-world data (RWD) in HealthVerity Marketplace, it may appear...
Electronic Health Records (EHR): What they are and how to use them in real-world data Electronic...
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
In this edition of our Ask an Expert series, we turn to Emery Niemiec, Senior Director,...
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and...
Government health agencies are increasingly turning to real-world data (RWD) for public health...
HealthVerity recently introduced HealthVerity Notes, our newest product designed to unlock the...
AI-driven mortality models are supposed to provide accurate, data-backed insights into patient...
Capturing the true complexity of psoriasis in the real world Psoriasis is a common chronic inflammatory disease affecting roughly 2-3% of U.S. adults (over 7.5 million people) making it one of the most prevalent immune-mediated conditions in the coun...